[Liver Injury Risk Factors in Amyotrophic Lateral Sclerosis Patients Treated with Riluzole].

In conclusion, treatment of ALS patients with riluzole, smoking habits, and concurrent use of CYP1A2 inhibitors are independent liver injury risk factors. Further studies on liver injury are warranted in ALS patients treated with riluzole to comprehensively understand the underlying mechanisms of riluzole-associated liver toxicity. PMID: 32612057 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32612057?dopt=Abstract

Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 3, 2020 Category: Drugs & Pharmacology Authors: Kawano C, Isozaki Y, Nakagawa A, Hirayama T, Nishiyama K, Kuroyama M Tags: Yakugaku Zasshi Source Type: research